Liver surgery for colorectal liver metastases
Authors:
V. Třeška
Authors place of work:
Chirurgická klinika, Univerzita Karlova, LF v Plzni, FN Plzeň
Published in the journal:
Rozhl. Chir., 2018, roč. 97, č. 4, s. 149-155.
Category:
Review
Summary
Introduction:
Resection of colorectal liver metastases (CLM) is the only radical treatment. Nevertheless, radical liver surgery for CLM is possible in about 30% of patients with 40–50% five year overall survival. The results of liver surgery depend on various factors including the extent of CLM, characteristics of the primary colorectal carcinoma, exact preoperative diagnosis and optimal timing of the surgery by a multidisciplinary team. The aim of this review is to summarize the current possibilities of liver surgery and to point out the possibilities of increasing resectability of primary non-resectable CLM.
Methods:
The definition of CLM resectability and the possibilities of perioperative oncological treatment in primary and potentially resectable CLM are discussed based on our long-term experience and experience published in the literature. The methods of increasing resectability of primary non-resectable CLM, liver first and simultaneous resections, liver transplantation, ultrasound-guided enhanced one-stage hepatectomy, resections of extrahepatic metastases, tumour recurrence after liver surgery, palliative thermoablation and embolization methods are also discussed. The author defines the predictive factors of liver surgery and underlines the importance of thorough follow-up of patients after liver surgery for CLM.
Conclusion:
Currently, liver surgery is the main treatment option of CLM. Although the procedure is associated with many limits, these limits can be influenced by the strategy and tactics of the diagnostic process and treatment methods as determined by the multidisciplinary team.
Key words:
colorectal liver metastases – diagnosis – treatment – results – predictive factors
Zdroje
1. Moris D, Pawlik TM. Personalized treatment in patients with colorectal liver metastases. J Surg Res 2017;216:26−9.
2. Adam R. LiverMetSurvey, Statistics December 2015. Available from: www.livermetsurvey.org
3. Sofue K, Tsurusaki M, Murakami T, et al. Does Gadoxetic acid-enhanced 3.0T MRI in addition to 64-detector-row contrast-enhanced CT provide better diagnostic performance and change the therapeutic strategy for the preoperative evaluation of colorectal liver metastases? Eur Radiol 2014;24:2532−9.
4. Mentha G, Terraz S, Morel P, et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg. 2009; 96:95−103.
5. Adam R. Colorectal cancer with synchronous liver metastases. Br J Surg 2007; 94:129−31.
6. Nordlinger B, Sorbye H, Glimelius B, et al. EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 22:371:1007−16.
7. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010;252:774−87.
8. Nagayama S, Hasegawa S, Hida K, et al. Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers. Int J Clin Oncol 2017;22:316−23.
9. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56:430−9.
10. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 10:26:5254−60.
11. Andres A, Toso C, Adam R, et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg 2012;256:772−8.
12. Pudil J, Batko S, Menclová K, et al. “Liver first” přístup v léčbě synchronních jaterních metastáz kolorektálního karcinomu. Rozhl Chir 2015; 94:522−5.
13. Straka M, Skrovina M, Soumarova R, et al. Up front hepatectomy for metastatic rectal carcinoma − reversed, liver first approach. Early experience with 15 patients. Neoplasma 2014; 61:447−52.
14. Quan D, Gallinger S, Nhan C, et al. Surgical Oncology Program at Cancer Care Ontario. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 2012;151:860−70.
15. Imai K, Castro Benitez C, Allard MA, et al. Potential of a cure in patients with colorectal liver metastases and concomitant extrahepatic disease. J Surg Oncol 2017;115:488−96.
16. Andres A, Mentha G, Adam R, et al. Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg 2015;102:691−9.
17. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012;255:405−14.
18. Ironside N, Bell R, Bartlett A, et al. Systematic review of perioperative and survival outcomes of liver resections with and without preoperative portal vein embolization for colorectal metastases. HPB (Oxford) 2017;19:559−66.
19. Schadde E, Ardiles V, Slankamenac K, et al. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg 2014;38:1510−9.
20. Tschuor Ch, Croome KP, Sergeant G, et al. Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion − an extension of the ALPPS approach. Eur J Surg Oncol 2013;39:1230−5.
21. de Santibañes E, Alvarez FA, Ardiles V, et al. Inverting the ALPPS paradigm by minimizing first stage impact: the Mini-ALPPS technique. Langenbecks Arch Surg 2016;401:557−63.
22. Treska V, Liska V, Lysak D, et al. Portal vein embolization with application of haematopoietic stem cells in patients with primarily non-resectable colorectal liver metastases. Anticancer Research 2014; 34:7279−86.
23. Treska V. Methods to increase future liver remnant volume in patients with primarily unresectable colorectal liver metastases: Current state and future perspectives. Anticancer Res 2016;36:2065−72.
24. Torzilli G, Adam R, Viganò L, et al. Surgery of colorectal liver metastases: Pushing the limits. Liver Cancer 2016;6:80−9.
25. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010;51:1237−43.
26. Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013;257:800−6.
27. Foss A, Lerut JP. Liver transplantation for metastatic liver malignancies. Curr Opin Organ Transplant 2014;19:235−44.
28. Line PD, Hagness M, Berstad AE, et al. Novel concept for partial liver transplantation in nonresectable colorectal liver metastases: The RAPID concept. Ann Surg 2015;262:5−9.
29. Aissou S, Cartier V, Hamy A, et al. Radiofrequency in the management of colorectal liver metastases: A 10-year experience at a single center. Surg Technol Int 2016;26:99−105.
30. Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009;197:728−36.
31. Vavra P, Nowakova J, Ostruszka P, et al. Colorectal cancer liver metastases: laparoscopic and open radiofrequency-assisted surgery. Wideochir Inne Tech Maloinwazyjne 2015;10:205−12.
32. Fukami Y, Kaneoka Y, Maeda A, et al. Postoperative complications following aggressive repeat hepatectomy for colorectal liver metastasis have adverse oncological outcomes. Surg Today 2017;47:99−107.
33. Jones RP, Jackson R, Dunne DF, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99:477−86.
34. Saiura A, Yamamoto J, Koga R, et al. Favorable outcome after repeat resection for colorectal liver metastases. Ann Surg Oncol 2014;21:4293−9.
35. Hof J, Wertenbroek MW, Peeters PM, et al. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br J Surg 2016;103:1055−62.
36. Pereira AA, Rego JF, Morris V, et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 2015;112:424−8.
37. Bruin SC, He Y, Mikolajewska-Hanclich I, et al. Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer 2011;12;105:281−7.
38. Brudvik KW1, Kopetz SE, Li L, et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102:1175−83.
39. Azoulay D, Bhangui P, Pascal G, et al. The impact of expanded indications on short-term outcomes for resection of malignant tumours of the liver over a 30 year period. HPB (Oxford) 2017;19:638−48.
40. Loes IM, Immervoll H, Sorbye H, et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer 2016;139:647−56.
41. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014;120:2316−24.
42. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623−32.
43. Blazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008;26:5344−51.
44. Yokoyama N, Shirai Y, Ajioka Y, et al. Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer 2002;94:1642−7.
45. Vermeulen PB, Colpaert C, Salgado R, et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol. 2001;195:336−42.
46. Liška V, Emingr M, Skála M, et al. Jaterní metastázy karcinomů kolon a rekta z pohledu rozdílů v klinických parametrech. Rozhl Chir 2016;95:69−79.
Štítky
Surgery Orthopaedics Trauma surgeryČlánok vyšiel v časopise
Perspectives in Surgery
2018 Číslo 4
- Metamizole vs. Tramadol in Postoperative Analgesia
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Spasmolytic Effect of Metamizole
Najčítanejšie v tomto čísle
- Surgical treatment of midshaft clavicular fractures using intramedullary nail
- Artificial bowel sphincter ten years later
- Liver surgery for colorectal liver metastases
- Radiotherapy in the treatment of rectal cancer − is it time to move on?